Table 1.
Comparison of demographics and clinical characteristics between remitters and non-remitters
| Demographics and clinical characteristics | Remitter (n=23) | Non-remitter (n=28) | Total (n=51) |
|---|---|---|---|
| Age (years) | 40.3 (12.6) | 41.5 (10.8) | 40.9 (11.5) |
| Women | 17 (73.9%) | 18 (64.3%) | 35 (68.6%) |
| Education (years) | 14.9 (2.4) | 14.1 (2.2) | 14.5 (2.3) |
| Employed | 13 (56.5%) | 20 (71.4%) | 33 (64.7%) |
| Unemployed | 3 (13.0%) | 5 (17.8%) | 8 (15.7%) |
| Housewife and student | 7 (30.4%) | 3 (10.7%) | 10 (19.6%) |
| Marital status | |||
| Married | 13 (56.5%) | 11 (39.3%) | 24 (47.1%) |
| Separated, divorced, widowed | 1 (4.3%) | 4 (14.3%) | 5 (9.8%) |
| Single | 9 (39.1%) | 13 (46.4%) | 22 (43.1%) |
| Cohabiting | 20 (87.0%) | 19 (67.9%) | 39 (76.5%) |
| Family history of psychiatric disorders | 8 (34.7%) | 13 (46.4%) | 21 (41.2%) |
| Total number of lifetime depressive episodes | 1.4 (0.8) | 1.7 (1.4) | 1.6 (1.2) |
| Median duration of current depressive episode (months) | 7 | 13.5 | 9 |
| Depression severity at baseline | |||
| GRID-HAMD21 | 10.0 (7.9) | 17.1 (7.0) | 13.9 (8.2) |
| BDI-II | 17.8 (12.1) | 27.8 (11.0) | 23.6 (12.6) |
| QIDS-SR16 | 8.8 (6.9) | 14.0 (5.1) | 11.6 (6.5) |
| Degree of functional impairment at baseline | |||
| SDS total | 11.8 (7.8) | 16.2 (7.3) | 14.2 (7.8) |
| SDS work domain | 4.5 (3.2) | 6.1 (2.9) | 5.3 (3.1) |
| SDS social life domain | 4.5 (2.8) | 5.9 (2.8) | 5.3 (2.8) |
| SDS family life domain | 2.9 (2.7) | 4.2 (2.7) | 3.6 (2.7) |
| Number of antidepressant treatment courses for current episode | |||
| 0 | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| 1–2 | 20 (87.0%) | 14 (50.0%) | 34 (66.7%) |
| 3–4 | 2 (8.7%) | 11 (39.2%) | 13 (25.4%) |
| 5 or more | 1 (4.3%) | 2 (7.1%) | 3 (5.9%) |
| Duration of antidepressant treatment for current episode | |||
| <6 months | 16 (69.6%) | 12 (42.9%) | 28 (54.9%) |
| 6 months to 1 year | 4 (17.3%) | 3 (10.7%) | 7 (13.7%) |
| 1–2 years | 1 (4.3%) | 6 (21.4%) | 7 (13.7%) |
| >2 years | 2 (8.7%) | 7 (25.0%) | 9 (17.6%) |
| Used antidepressant at baseline | |||
| SSRI | |||
| Sertraline | 15 (65.2%) | 13 (46.4%) | 28 (54.9%) |
| Paroxetine | 0 (0.0%) | 2 (7.1%) | 2 (3.9%) |
| Fluvoxamine | 1 (4.3%) | 0 (0.0%) | 1 (2.0%) |
| Escitalopram | 2 (8.7%) | 0 (0.0%) | 2 (3.9%) |
| SNRI | |||
| Duloxetine | 2 (8.7%) | 3 (10.7%) | 5 (9.8%) |
| Milnacipran | 1 (4.3%) | 1 (3.6%) | 2 (3.9%) |
| TCA | |||
| Amoxapine | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Nortriptyline | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Amitriptyline | 1 (4.3%) | 1 (3.6%) | 2 (3.9%) |
| Other | |||
| Mirtazapine | 1 (4.3%) | 3 (10.7%) | 4 (7.8%) |
| Trazodone | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Mianserin | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
| Treatment modality at 6 months post baseline | |||
| Antidepressant therapy only | 20 (87.0%) | 25 (89.3%) | 45 (88.2%) |
| Combination of antidepressant therapy and CBT | 3 (13.0%) | 2 (7.1%) | 5 (9.8%) |
| CBT only | 0 (0.0%) | 1 (3.6%) | 1 (2.0%) |
Notes: Data are shown as mean (SD) or n (%). Remitters means patients who achieved remission by the 6-month assessment (GRID-HAMD21 ≤7).
Abbreviations: BDI-II, Beck Depression Inventory, Second Edition; CBT, cognitive behavioral therapy; GRID-HAMD21, 21-item GRID-Hamilton Depression Rating Scale; QIDS-SR16, 16-Item Quick Inventory Depressive Symptomatology (Self-Report); SDS, Sheehan Disability Scale; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants.